Tag:
Actelion
Latest Headlines
Latest Headlines
The biggest R&D spenders in biotech
Last year the top 10 biotechs in the world spent $10.2 billion on R&D, up a whopping 13% over their $8.9 billion track record in 2010.
Actelion surges as positive PhIII macitentan data reignites buyout buzz
The data signals to investors that the Swiss company can be ready for the loss of patent protection on its primary earner with the introduction of another blockbuster.
UPDATED: Merck drug homes in on new baldness target
Drug developers have a new target to pursue in their search for remedies against baldness, which afflicts most males to some degree.
Swiss biotech Actelion grabs rights to biologic in $68.5M deal
With plans to beef up its limited commercial offerings, Swiss biotech Actelion ( $ATLN ) has secured rights in certain countries to Auxilium's ( $AUXL ) biotech drug for treating tissue buildups...
Actelion hunts for answers about 120 deaths in key drug trial
Actelion ( $ATLN ) CEO Jean-Paul Clozel has been clear about the importance of macitentan for the Swiss biotech's future in the blockbuster market for pulmonary arterial hypertension (PAH) drugs. So
Analysts give Actelion's key lung drug 63% odds of success
Swiss biotech Actelion ( $ATLN ) could use a win for its experimental lung drug. In need for a new product to follow its big hit Tracleer, the company's big moment for its lung disease treatment
Actelion braces for looming pivotal data on blockbuster macitentan program
Actelion's ( $ATLN ) approach to the year ahead might best be described as hoping for the best while preparing for the worst. Crucial late-stage data on macitentan is due to read out in the second
PhIII ALS failure costs Trophos a $250M buyout deal with Actelion
France's Trophos says that a Phase III study of its lead drug for ALS (Lou Gehrig's disease) failed to hit its primary endpoint, and the swing and a miss will cost its investors up to $250 million.
Actelion drug flunks PhII but safety data bolsters confidence in blockbuster PhIII
Typically, when a drug fails a mid-stage study and the biotech announces it will shelve the program as a result, it's counted as a black mark. But there isn't anything typical about Actelion's
Garnier pledges active role on Actelion board
Former GlaxoSmithKline chief Jean-Pierre Garnier ( photo ) easily won election to the board of Actelion, the Swiss drugmaker that has been under seige by some dissident shareholders. In fact, none of
